However, TLR agonists in the rWTC-MBTA preparation can promote Th1-mediated inflammatory responses and activate APCs in TME, which can lead to better tumor infiltration and improved functioning of the immune effector cells, like NK cells and CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.